Fairvalue-Calculator Fairvalue-Calculator
EN DE

Hanmi Pharm. Co (128940) Fair Value & Analysis

Healthcare · KR · Market cap 6.3T KRW

Price377,000 KRW
Fair Value279,997 KRW
Upside-25.7%
Quality83/100
Evidence: Medium Range 159,126 KRW – 367,718 KRW

Analysis

Hanmi Pharm. Co (128940) currently trades at 377,000 KRW, while our model-based Fair Value estimate is 279,997 KRW — implying the stock looks roughly 25.7% overvalued today. We read business quality at 83/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +885% Jiangsu Hengrui Pharmaceuticals Co (600276) -44% Sun Pharmaceutical Industries Limited (SUNPHARMA) -49% Zoetis Inc (Z1TS34) -75% Hansoh Pharmaceutical Group (3692) -18% United Therapeutics Corporation (U2TH34) -79%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.